Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Hudson |
RCV001261931 | SCV001439274 | uncertain significance | Cerebrooculofacioskeletal syndrome 2 | 2020-08-26 | criteria provided, single submitter | research | ACMG codes:PM2 |
Labcorp Genetics |
RCV001880026 | SCV002288883 | uncertain significance | not provided | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 154 of the ERCC2 protein (p.His154Gln). This variant is present in population databases (rs139263710, gnomAD 0.1%). This variant has not been reported in the literature in individuals affected with ERCC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 982306). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001880026 | SCV005334002 | uncertain significance | not provided | 2024-03-28 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 34930662, 27085493) |
Fulgent Genetics, |
RCV005014315 | SCV005648424 | uncertain significance | Cerebrooculofacioskeletal syndrome 2; Xeroderma pigmentosum, group D; Trichothiodystrophy 1, photosensitive | 2024-06-21 | criteria provided, single submitter | clinical testing |